# EDGAR Filing Document

**Accession Number:** 0001651311
**File Stem:** 0001193125-26-008212
**Filing Date:** 2026-1
**Character Count:** 2845
**Document Hash:** 217f30828857248b48cafa61c99c5db9
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-008212.hdr.sgml**: 20260109

**ACCESSION NUMBER**: 0001193125-26-008212

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260109

**DATE AS OF CHANGE**: 20260109

**EFFECTIVENESS DATE**: 20260109

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Merus N.V.
- **CENTRAL INDEX KEY:** 0001651311
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** P7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37773
- **FILM NUMBER:** 26521273

**BUSINESS ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** 3584 CM UTRECHT
- **STATE:** DE
- **BUSINESS PHONE:** 31 030 253 8800

**MAIL ADDRESS:**
- **STREET 1:** YALELAAN 62
- **CITY:** 3584 CM UTRECHT
- **STATE:** DE

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Merus B.V.
- **DATE OF NAME CHANGE:** 20150819

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

**FORM 15** 

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION** 

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)** 

**OF THE SECURITIES EXCHANGE ACT OF 1934.** 

**Commission File Number: 001-37773** 

## Merus N.V.
**(Exact name of registrant as specified in its charter)** 

**Uppsalalaan 17** 

**3584 CT Utrecht** 

**The Netherlands** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Common Shares, €0.09 nominal value per share** 

**(Title of each class of securities covered by this Form)** 

**None** 

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)** 

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
|  Rule 12g-4(a)(1) | ☒ |
|  Rule 12g-4(a)(2) | ☐ |
|  Rule 12h-3(b)(1)(i) | ☒ |
|  Rule 12h-3(b)(1)(ii) | ☐ |
|  Rule 15d-6 | ☐ |
|  Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: Zero (0).

Pursuant to the requirements of the Securities Exchange Act of 1934, Merus B.V. (as successor to Merus N.V.) has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Date: January 9, 2026 | **Merus B.V.**<br> as successor to Merus N.V. | **Merus B.V.**<br> as successor to Merus N.V. |
|  | By: | /s/ Jan G. J. van de Winkel |
|  | Name: | Jan G. J. van de Winkel |
|  | Title: | Managing Director |

---